BlueRock Therapeutics

Seth Ettenberg, Ph.D., CEO

April 12 | 11:45am | BioCentriq Ballroom

Cambridge, MA


In-Person Presentation

BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. Our cell+gene platform is harnessing the power of cells to create a pipeline of new medicines for patients suffering from neurological, cardiovascular, immunological, and ophthalmic diseases. Our lead clinical program, bemdaneprocel, (BRT-DA01) is in Phase 1 clinical trials for Parkinson’s disease. We were founded in 2016 by Versant Ventures and Bayer AG and became a wholly owned, independently operated subsidiary of Bayer AG in late 2019 as a cornerstone of its newly formed Cell & Gene Therapy Platform. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves.

By using this website you agree to accept our Privacy Policy and Terms & Conditions